Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
0.18
Industry P/E
--
Debt to Equity
0
ROE
-0.5 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-149.69 Mln
EBITDA
$-169.08 Mln
Net Profit
$-162.42 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
| -56.74 | -20.09 | -52.90 | -67.54 | -83.25 | -72.04 | -51.74 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Galmed Pharmaceuticals - ADR
| -93.93 | -72.53 | -41.48 | -46.19 | -15.37 | -25.24 | 160.68 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III... study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Address: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608 Read more
Co-Founder, President, CEO & Chairman
Mr. Allen Baharaff
Co-Founder, President, CEO & Chairman
Mr. Allen Baharaff
Headquarters
Ramat Gan
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Galmed Pharmaceuticals Ltd - ADR stood at $ 35 Mln as on 31-Mar-25
The share price of Galmed Pharmaceuticals Ltd - ADR is $1.38 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Galmed Pharmaceuticals Ltd - ADR has given a return of -83.25% in the last 3 years.
Galmed Pharmaceuticals Ltd - ADR has a market capitalisation of $ 3 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Galmed Pharmaceuticals Ltd - ADR is 0.18 times as on 16-Apr-2025, a 92% discount to its peers’ median range of 2.35 times.
Since, TTM earnings of Galmed Pharmaceuticals Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Galmed Pharmaceuticals Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of Galmed Pharmaceuticals Ltd - ADR.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Address: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608
The CEO & director of Mr. Allen Baharaff. is Galmed Pharmaceuticals Ltd - ADR, and CFO & Sr. VP is Mr. Allen Baharaff.
There is no promoter pledging in Galmed Pharmaceuticals Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Galmed Pharmaceuticals Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-54.37
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Galmed Pharmaceuticals Ltd - ADR was $0 Mln.
$0.02
(
